ArticleACS nano2011
Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant.
Article in ACS nano, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 130 citations in OpenAlex.
- Inhalable and bioactive lipid-nanomedicine based on bergapten for targeted acute lung injury therapy via orchestrating macrophage polarization.Bioactive materials · 2025Article
- Determinants and mechanisms of inorganic nanoparticle translocation across mammalian biological barriers.Archives of toxicology · 2023Review
- Lung surfactant as a biophysical assay for inhalation toxicology.Current research in toxicology · 2023Review
- Evaluating the Impact of Hydrophobic Silicon Dioxide in the Interfacial Properties of Lung Surfactant Films.Environmental science & technology · 2022Article
- Pulmonary surfactant as a versatile biomaterial to fight COVID-19.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Synthesis, Characterization, Functionalization and Bio-Applications of Hydroxyapatite Nanomaterials: An Overview.International journal of nanomedicine · 2022Review
- An adverse outcome pathway for lung surfactant function inhibition leading to decreased lung function.Current research in toxicology · 2021Article
- Revealing the pulmonary surfactant corona on silica nanoparticles by cryo-transmission electron microscopy.Nanoscale advances · 2020Article
- Impact of Nanoparticle Uptake on the Biophysical Properties of Cell for Biomedical Engineering Applications.Scientific reports · 2019Article
- Electronic cigarette vapor alters the lateral structure but not tensiometric properties of calf lung surfactant.Respiratory research · 2017Article
- Protein corona: implications for nanoparticle interactions with pulmonary cells.Particle and fibre toxicology · 2017Article
- Early Assessment and Correlations of Nanoclay's Toxicity to Their Physical and Chemical Properties.ACS applied materials & interfaces · 2017Article
- Calcium Phosphate as a Key Material for Socially Responsible Tissue Engineering.Materials (Basel, Switzerland) · 2016Article
- The role of natural processes and surface energy of inhaled engineered nanoparticles on aggregation and corona formation.NanoImpact · 2016Article
- Response of Human Osteoblast to n-HA/PEEK--Quantitative Proteomic Study of Bio-effects of Nano-Hydroxyapatite Composite.Scientific reports · 2016Article
- Calf Lung Surfactant Recovers Surface Functionality After Exposure to Aerosols Containing Polymeric Particles.Journal of aerosol medicine and pulmonary drug delivery · 2016Article
- Effects of graphene oxide nanosheets on the ultrastructure and biophysical properties of the pulmonary surfactant film.Nanoscale · 2015Article
- Biophysical influence of airborne carbon nanomaterials on natural pulmonary surfactant.ACS nano · 2015Article
- Phospholipid composition modulates carbon nanodiamond-induced alterations in phospholipid domain formation.Langmuir : the ACS journal of surfaces and colloids · 2015Article
- Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis.Critical reviews in therapeutic drug carrier systems · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Inhaled nanoparticles (NPs) must first interact with the pulmonary surfactant (PS) lining layer that covers the entire internal surface of the respiratory tract and plays an important role in surface tension reduction and host defense. Interactions with the PS film determine the subsequent clearance, retention, and translocation of the inhaled NPs and hence their potential toxicity. To date, little is known how NPs interact with PS, and whether or not NPs have adverse effects on the biophysical function of PS. We found a time-dependent toxicological effect of hydroxyapatite NPs (HA-NPs) on a natural PS, Infasurf, and the time scale of surfactant inhibition after particle exposure was comparable to the turnover period of surfactant metabolism. Using a variety of in vitro biophysicochemical characterization techniques, we have determined the inhibition mechanism to be due to protein adsorption onto the HA-NPs. Consequently, depletion of surfactant proteins from phospholipid vesicles caused conversion of original large vesicles into much smaller vesicles with poor surface activity. These small vesicles, in turn, inhibited biophysical function of surfactant films after adsorption at the air-water interface. Cytotoxicity study found that the HA-NPs at the studied concentration were benign to human bronchial epithelial cells, thereby highlighting the importance of evaluating biophysical effect of NPs on PS. The NP-PS interaction mechanism revealed by this study may not only provide new insight into the toxicological study of nanoparticles but also shed light on the feasibility of NP-based pulmonary drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.